CymaBay Therapeutics, Inc.
Symbol: CBAY
NASDAQ
32.48
USDMarktpreis heute
-32.9591
P/E-Verhältnis
0.0000
PEG-Verhältnis
3.73B
MRK Kapital
- 0.00%
DIV Rendite
CymaBay Therapeutics, Inc. (CBAY) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1283.24 | 394.3 | 135.5 | 186.5 | ||||||||||||
balance-sheet.row.short-term-investments | 708.35 | 187.7 | 115.2 | 60.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 35.01 | 9.5 | 2.6 | 4.6 | ||||||||||||
balance-sheet.row.total-current-assets | 1318.25 | 403.8 | 138.1 | 191.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.83 | 5.7 | 0.9 | 1.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 22.36 | 22.4 | 0 | 8.1 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 9.26 | 2.8 | 2.9 | 1.7 | ||||||||||||
balance-sheet.row.total-non-current-assets | 39.45 | 30.9 | 3.8 | 11.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.account-payables | 12.78 | 3.8 | 1.1 | 2.7 | ||||||||||||
balance-sheet.row.short-term-debt | 11.12 | 10 | 0.7 | 0.6 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 397.14 | 99.2 | 90.3 | 51 | ||||||||||||
Deferred Revenue Non Current | 3.3 | 1.1 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -203.34 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 58.31 | 21.3 | 13.7 | 15.1 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 405.76 | 105.6 | 90.3 | 51 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 6.43 | 5.3 | 0.7 | 1.3 | ||||||||||||
balance-sheet.row.total-liab | 526.66 | 142.4 | 105.7 | 69.4 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.06 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3718.63 | -978.2 | -872.9 | -766.9 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.11 | 0.1 | -0.3 | 0 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4549.72 | 1270.3 | 909.3 | 899.8 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1357.7 | - | - | - | ||||||||||||
Total Investments | 730.71 | 210.1 | 115.2 | 68.8 | ||||||||||||
balance-sheet.row.total-debt | 413.58 | 114.5 | 90.9 | 51.6 | ||||||||||||
balance-sheet.row.net-debt | -161.31 | -92 | 70.6 | -74.2 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -105.37 | -105.4 | -106 | -90 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.77 | -2.7 | 0 | 0.6 | ||||||||||||
cash-flows.row.stock-based-compensation | 15.23 | 15.2 | 9.5 | 10 | ||||||||||||
cash-flows.row.change-in-working-capital | 5.63 | 5.6 | -2.3 | 6.4 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | 2.73 | 2.7 | -1.4 | 2.3 | ||||||||||||
cash-flows.row.other-working-capital | 2.9 | 2.9 | -0.9 | 4 | ||||||||||||
cash-flows.row.other-non-cash-items | 19.06 | 14 | 14 | 2.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -72.53 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.acquisitions-net | -2.11 | -7.9 | -0.9 | 0.6 | ||||||||||||
cash-flows.row.purchases-of-investments | -305.67 | -305.7 | -175 | -78.1 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 219.55 | 219.6 | 129.1 | 126.8 | ||||||||||||
cash-flows.row.other-investing-activites | 2.11 | 7.9 | 0.9 | -0.6 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -86.57 | -86.6 | -46 | 48.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -25 | -47.7 | ||||||||||||
cash-flows.row.common-stock-issued | 339.36 | 345.8 | -0.5 | 70.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -0.5 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -25 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 7.46 | 335.1 | 75.5 | 95.7 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 345.77 | 345.8 | 24.6 | 118.5 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 26.59 | -0.4 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 186.24 | 186.2 | -105.5 | 97.6 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 574.89 | 206.5 | 20.3 | 125.8 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 388.64 | 20.3 | 125.8 | 28.2 | ||||||||||||
cash-flows.row.operating-cash-flow | -72.53 | -72.5 | -84.1 | -69.4 | ||||||||||||
cash-flows.row.capital-expenditure | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.free-cash-flow | -72.98 | -73 | -84.2 | -69.5 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 31.07 | 31.1 | 0 | 0 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
income-statement-row.row.gross-profit | 30.39 | 30.4 | -0.7 | -0.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 80.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 51.95 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 132.7 | 132.1 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 132.75 | 132.8 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.interest-income | 13.49 | 13.5 | 2 | 0.2 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 3.18 | 0.7 | 2 | 0.9 | ||||||||||||
income-statement-row.row.ebitda-caps | -94.8 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -101.68 | -101.7 | -93.1 | -87.6 | ||||||||||||
income-statement-row.row.income-before-tax | -105.37 | -105.4 | -106 | -90 | ||||||||||||
income-statement-row.row.income-tax-expense | 11.99 | 0 | 12.9 | 2.6 | ||||||||||||
income-statement-row.row.net-income | -111.68 | -105.4 | -118.9 | -92.6 |
Häufig gestellte Frage
Wie hoch ist die CymaBay Therapeutics, Inc. (CBAY) Gesamtvermögen?
CymaBay Therapeutics, Inc. (CBAY) Gesamtvermögen ist 434686000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 57000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.978.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.644.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -3.594.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -3.272.
Was ist der CymaBay Therapeutics, Inc. (CBAY) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -105370000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 114494000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 132071000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 206535000.000.